Coronavirus / COVID

We asked a simple question to our IDWeek experts: has COVID-19 taken attention away from any greater infectious disease issues?

A Medicare program provided more point-of-care testing devices this summer. Yet, even hot-spot facilities are far more likely to receive results in ≥3 days than 1.

Virologists have identified a gene encoded by SARS-CoV-2 that enables it, but not SARS-CoV or Influenza A viruses, to inhibit interferon-based immune response

The investigational antibody used to treat President Trump shows it reduced viral load and medical visits.

A new study shows disproportionate impact of the virus to this group.

As researchers develop ways to assess the effects of the pandemic on criminal activity, a new report documents the impact on those incarcerated.

These vital cells that are recovered from COVID-19 patients might be able to help people with compromised immune systems due to cancer therapy or transplantation.

While this trial for hospitalized COVID-19 patients has been discontinued, Lilly is continuing their other trials with the medication for COVID-19 treatment.

A research team recently focused on how the pandemic intensifies the effects felt by those already marginalized or vulnerable, as it is the intersection of biological and socioecological factors.

The company is planning to move forward after receiving a recommendation from the DSMB to start up the trial again.

A case study examines a treatment for a hospitalized case of the virus.

Autoantibodies that attack type 1 interferons, neutralizing the immune system’s ability to block the SARS-CoV-2 virus, were present in 10% of patients with life-threatening coronavirus diseases 2019 (COVID-19) pneumonia, a new study found.

New data may evidence oral care as a therapeutic measure to reduce bacterial and viral spread.

The hospital found just 2 cases in their first 12 weeks were borne in the facility. A study author provides insight.

An investigator shares detail into how the neutralizing, immune-signaling molecule may provide continued success against the virus.

Ravina Kullar, PharmD, MPH, reflects on rapid advances in COVID-19 treatment understanding during IDWeek 2020.

New data show the pandemic, and a lack of efficacious therapies, did harm to 4 years' worth of stewardship.

The conclusion to the independent safety review punctuates a 50-day period of scrutiny and discussion around 2 non-fatal adverse events reported in patients.

Its phase 3 COVE trial enrollment is complete and the company is working towards its goal of FDA approval.

Reports of hospitalized older adults with COVID-19 who do not experience the classic symptoms are on the rise.

A prospective study looked at the association of contract nursing and SARS-CoV-2 outbreaks.

The full approval is based on 3 randomized controlled trials showing benefit of remdesivir compared with placebo across multiple outcome assessments.

How has the COVID-19 pandemic affected clinical trial site restrictions, drug delivery, dosing, patient monitoring, and follow-up?

New data presented at IDWeek showed more than half observed households with a COVID-19 case reported a secondary infection, oftentimes within 3 days.

Phase 1 data and a history of benefit for worsening respiratory infections show promise for the therapy.